Olema Pharmaceuticals (OLMA) Gains from Sales and Divestitures (2020 - 2024)
Olema Pharmaceuticals (OLMA) reported Gains from Sales and Divestitures of $92659.0 for Q4 2024, down 51.56% year-over-year from $191296.0 in Q1 2024, and little changed quarter-over-quarter from $92659.0 in Q3 2024.
Olema Pharmaceuticals (OLMA) Gains from Sales and Divestitures (2020 - 2024) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 5 years of Gains from Sales and Divestitures data on file, last reported at $92659.0 in Q4 2024.
- Gains from Sales and Divestitures for Q4 2024 came in at $92659.0, down 51.56% year-over-year; the trailing twelve-month figure through Dec 2024 was $92659.0 (down 51.56% YoY), and the FY2024 annual result was $92659.0, down 51.56% from the prior year.
- Gains from Sales and Divestitures steadied at $92659.0 in Q4 2024 per OLMA's latest filing, from $92659.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $242109.0 in Q4 2021 and troughed at $6990.0 in Q1 2021.
- A 5-year average of $94458.6 and a median of $73230.0 in 2020 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2021 and 2022: Gains from Sales and Divestitures soared 616.66% in 2021, then slumped 74.42% in 2022.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $53801.0 in 2020, then soared by 350.01% to $242109.0 in 2021, then decreased by 18.52% to $197274.0 in 2022, then declined by 3.03% to $191296.0 in 2023, then plunged by 51.56% to $92659.0 in 2024.
- Business Quant data shows OLMA's Gains from Sales and Divestitures at $92659.0 in Q4 2024, $92659.0 in Q3 2024, and $52308.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 92,659.00 |
| Dec 31, 2024 | 92,659.00 |
| Sep 30, 2024 | 92,659.00 |
| Sep 30, 2024 | 92,659.00 |
| Jun 30, 2024 | 52,308.00 |
| Jun 30, 2024 | 52,308.00 |
| Mar 31, 2024 | 40,351.00 |
| Mar 31, 2024 | 40,351.00 |
| Dec 31, 2023 | 191,296.00 |
| Dec 31, 2023 | 191,296.00 |
| Sep 30, 2023 | 49,318.00 |
| Sep 30, 2023 | 49,318.00 |
| Jun 30, 2023 | 98,637.00 |
| Jun 30, 2023 | 98,637.00 |
| Mar 31, 2023 | 49,318.00 |
| Mar 31, 2023 | 49,318.00 |
| Dec 31, 2022 | 197,274.00 |
| Dec 31, 2022 | 197,274.00 |
| Sep 30, 2022 | 49,318.00 |
| Sep 30, 2022 | 49,318.00 |